Graft failure after allogeneic hematopoietic cell transplantation

被引:136
作者
Mattsson, Jonas [2 ]
Ringden, Olle [1 ,2 ]
Storb, Rainer [3 ,4 ]
机构
[1] Karolinska Univ Hosp Huddinge, Div Clin Immunol, Karolinska Inst, SE-14186 Stockholm, Sweden
[2] Karolinska Univ Hosp Huddinge, Ctr Allogene Stem Cell Transplantat, SE-14186 Stockholm, Sweden
[3] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA
[4] Univ Washington, Sch Med, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA
关键词
graft failure; rejection; allogeneic hematopoietic stem cell transplantation; major histocompatibility complex; reduced-intensity conditioning; cord blood transplant;
D O I
10.1016/j.bbmt.2007.10.025
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Graft failure is a significant complication following allogeneic hematopoietic cell transplantation (alloHCT). It may result from rejection caused by recipient T cells, natural killer (NK) cells, or antibodies. It is increased in HLA-mismatched grafts, unrelated grafts, T cell-replete transplants, sensitized patients, and in patients treated with reduced-intensity conditioning (RIC). In recipients of unrelated grafts, graft failure is increased in patients receiving major ABO blood group mismatched transplants (P =.008). Recent data also suggest that donor-specific antibodies to CD34(+)/VEGFR-2(+) cells may be involved in graft failure after alloHCT. Graft failure may be overcome by more intensified conditioning, increased cell dose, or more effective immunosuppression. With more frequent use of RIC, cord blood grafts and other HLA-mismatched transplants, graft failure is an increasing problem after alloHCT. (C) 2008 American Society for Blood and Marrow Transplantation.
引用
收藏
页码:165 / 170
页数:6
相关论文
共 63 条
[1]   Full haplotype-mismatched hematopoietic stem-cell transplantation: A phase II study in patients with acute leukemia at high risk of relapse [J].
Aversa, F ;
Terenzi, A ;
Tabilio, A ;
Falzetti, F ;
Carotti, A ;
Ballanti, S ;
Felicini, R ;
Falcinelli, F ;
Velardi, A ;
Ruggeri, L ;
Aloisi, T ;
Saab, JP ;
Santucci, A ;
Perruccio, K ;
Martelli, MP ;
Mecucci, C ;
Reisner, Y ;
Martelli, MF .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (15) :3447-3454
[2]  
BARGE AJ, 1989, BLOOD, V74, P1477
[3]   Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy [J].
Barker, JN ;
Weisdorf, DJ ;
DeFor, TE ;
Blazar, BR ;
McGlave, PB ;
Miller, JS ;
Verfaillie, CM ;
Wagner, JE .
BLOOD, 2005, 105 (03) :1343-1347
[4]   Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning [J].
Baron, F ;
Baker, JE ;
Storb, R ;
Gooley, TA ;
Sandmaier, BM ;
Maris, MB ;
Maloney, DG ;
Heimfeld, S ;
Oparin, D ;
Zellmer, E ;
Radich, JP ;
Grumet, FC ;
Blume, KG ;
Chauncey, TR ;
Little, MT .
BLOOD, 2004, 104 (08) :2254-2262
[5]   PREVENTION OF TRANSFUSION-INDUCED SENSITIZATION TO MINOR HISTOCOMPATIBILITY ANTIGENS ON DLA-IDENTICAL CANINE MARROW GRAFTS BY GAMMA-IRRADIATION OF MARROW DONOR BLOOD [J].
BEAN, MA ;
STORB, R ;
GRAHAM, T ;
RAFF, R ;
SALE, GE ;
SCHUENING, F ;
APPELBAUM, FR .
TRANSPLANTATION, 1991, 52 (06) :956-960
[6]   GAMMA-IRRADIATION OF PRETRANSPLANT BLOOD-TRANSFUSIONS FROM UNRELATED DONORS PREVENTS SENSITIZATION TO MINOR HISTOCOMPATIBILITY ANTIGENS ON DOG LEUKOCYTE ANTIGEN-IDENTICAL CANINE MARROW GRAFTS [J].
BEAN, MA ;
GRAHAM, T ;
APPELBAUM, FR ;
DEEG, HJ ;
SCHUENING, F ;
SALE, GE ;
STORB, R .
TRANSPLANTATION, 1994, 57 (03) :423-426
[7]   MARROW TRANSPLANTATION FROM RELATED DONORS OTHER THAN HLA-IDENTICAL SIBLINGS [J].
BEATTY, PG ;
CLIFT, RA ;
MICKELSON, EM ;
NISPEROS, BB ;
FLOURNOY, N ;
MARTIN, PJ ;
SANDERS, JE ;
STEWART, P ;
BUCKNER, CD ;
STORB, R ;
THOMAS, ED ;
HANSEN, JA .
NEW ENGLAND JOURNAL OF MEDICINE, 1985, 313 (13) :765-771
[8]   TRANSPLANTATION OF ALLOGENEIC PERIPHERAL-BLOOD STEM-CELLS MOBILIZED BY RECOMBINANT HUMAN GRANULOCYTE-COLONY-STIMULATING FACTOR [J].
BENSINGER, WI ;
WEAVER, CH ;
APPELBAUM, FR ;
ROWLEY, S ;
DEMIRER, T ;
SANDERS, J ;
STORB, R ;
BUCKNER, CD .
BLOOD, 1995, 85 (06) :1655-1658
[9]  
BOLGER GB, 1986, BONE MARROW TRANSPL, V1, P21
[10]   The role of disease stage in the response to donor lymphocyte infusions as treatment for leukemic relapse [J].
Carlens, S ;
Remberger, M ;
Aschan, J ;
Ringdén, O .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2001, 7 (01) :31-38